174 related articles for article (PubMed ID: 26914559)
1. In Patients With Low- to Intermediate-Risk Thyroid Cancer, a Preablative Thyrotropin Level of 30 μIU/mL Is Not Adequate to Achieve Better Response to 131I Therapy.
Zhao T; Liang J; Guo Z; Li T; Lin Y
Clin Nucl Med; 2016 Jun; 41(6):454-8. PubMed ID: 26914559
[TBL] [Abstract][Full Text] [Related]
2. Serum thyrotropin level of 30 μIU/mL is inadequate for preablative thyroglobulin to serve as a prognostic marker for differentiated thyroid cancer.
Zhao T; Liang J; Guo Z; Li J; Lin Y
Endocrine; 2016 Jul; 53(1):166-73. PubMed ID: 26782372
[TBL] [Abstract][Full Text] [Related]
3. Higher preablative serum thyroid-stimulating hormone level predicts radioiodine ablation effectiveness in patients with differentiated thyroid carcinoma.
Lawal IO; Nyakale NE; Harry LM; Lengana T; Mokgoro NP; Vorster M; Sathekge MM
Nucl Med Commun; 2017 Mar; 38(3):222-227. PubMed ID: 28002173
[TBL] [Abstract][Full Text] [Related]
4. [Significance of Dynamic Risk Assessment in the Follow-up of Non-distant Metastatic Differentiated Thyroid Cancer Patients with Intermediate and High Risk].
Liu JR; Liu YQ; Li H; Liang J; Lin YS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2020 Apr; 42(2):222-227. PubMed ID: 32385029
[No Abstract] [Full Text] [Related]
5. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
[TBL] [Abstract][Full Text] [Related]
6. Delayed initial radioiodine therapy related to incomplete response in low- to intermediate-risk differentiated thyroid cancer.
Li H; Zhang YQ; Wang C; Zhang X; Li X; Lin YS
Clin Endocrinol (Oxf); 2018 Apr; 88(4):601-606. PubMed ID: 29338092
[TBL] [Abstract][Full Text] [Related]
7. Could short thyroid hormone withdrawal be an effective strategy for radioiodine remnant ablation in differentiated thyroid cancer patients?
Piccardo A; Puntoni M; Ferrarazzo G; Foppiani L; Bottoni G; Altrinetti V; Treglia G; Naseri M; Dib B; Cabria M; Trimboli P; Massollo M; Giovanella L
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1218-1223. PubMed ID: 29460027
[TBL] [Abstract][Full Text] [Related]
8. Analysis of correlation factors influencing the outcome of initial 131I remnant ablative therapy in intermediate- to high-risk patients with papillary thyroid microcarcinoma.
Wu R; Liu W; Li N; Wang X; Sun D; Ji Y; Jia Q; Tan J; Zheng W
Nucl Med Commun; 2022 Jun; 43(6):669-674. PubMed ID: 35351838
[TBL] [Abstract][Full Text] [Related]
9. Pyramidal lobe decreases endogenous TSH stimulation without impact on radio-iodine therapy outcome in patients with differentiated thyroid cancer.
Sawicka-Gutaj N; Klimowicz A; Sowinski J; Oleksa R; Gryczynska M; Wyszomirska A; Czarnywojtek A; Ruchala M
Ann Endocrinol (Paris); 2014 Jul; 75(3):141-7. PubMed ID: 24997767
[TBL] [Abstract][Full Text] [Related]
10. Negative remnant
Lan W; Gege Z; Ningning L; Qiang W; Lin B; Qingjie M; Bin J
Ann Nucl Med; 2019 Feb; 33(2):112-118. PubMed ID: 30374858
[TBL] [Abstract][Full Text] [Related]
11. Combined use of radioiodine therapy and radiofrequency ablation in treating postsurgical thyroid remnant of differentiated thyroid carcinoma.
Long B; Li L; Yao L; Chen S; Yi H; Ye X; Xu D; Wu P
J Cancer Res Ther; 2015 Nov; 11 Suppl():C244-7. PubMed ID: 26612446
[TBL] [Abstract][Full Text] [Related]
12. Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation.
Vrachimis A; Schober O; Riemann B
Nuklearmedizin; 2012; 51(3):67-72. PubMed ID: 22294096
[TBL] [Abstract][Full Text] [Related]
13. The Influences of TSH Stimulation Level, Stimulated Tg Level and Tg/TSH Ratio on the Therapeutic Effect of
Zheng W; Rui Z; Wang X; Li N; Tan J; Liu W
Front Endocrinol (Lausanne); 2021; 12():601960. PubMed ID: 34177793
[TBL] [Abstract][Full Text] [Related]
14. UNFAVORABLE RESPONSES TO RADIOIODINE THERAPY IN N1B PAPILLARY THYROID CANCER: A PROPENSITY SCORE MATCHING STUDY.
Liu YQ; Li H; Liu JR; Lin YS
Endocr Pract; 2019 Dec; 25(12):1286-1294. PubMed ID: 31412228
[No Abstract] [Full Text] [Related]
15. Thyroglobulin levels measured at the time of remnant ablation to predict response to treatment in differentiated thyroid cancer after thyroid hormone withdrawal or recombinant human TSH.
Pitoia F; Abelleira E; Cross G
Endocrine; 2017 Jan; 55(1):200-208. PubMed ID: 27655291
[TBL] [Abstract][Full Text] [Related]
16. Preablative Stimulated Thyroglobulin Correlates to New Therapy Response System in Differentiated Thyroid Cancer.
Yang X; Liang J; Li T; Zhao T; Lin Y
J Clin Endocrinol Metab; 2016 Mar; 101(3):1307-13. PubMed ID: 26789779
[TBL] [Abstract][Full Text] [Related]
17. Low- and high-dose radioiodine therapy for low-/intermediate-risk differentiated thyroid cancer: a preliminary clinical trial.
Qu Y; Huang R; Li L
Ann Nucl Med; 2017 Jan; 31(1):71-83. PubMed ID: 27757803
[TBL] [Abstract][Full Text] [Related]
18. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of second 131I treatment in biochemical persistent differentiated thyroid cancer patients.
Gambale C; Prete A; Contartese L; Torregrossa L; Bianchi F; Molinaro E; Materazzi G; Elisei R; Matrone A
Eur Thyroid J; 2023 Dec; 12(6):. PubMed ID: 37855417
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of preablation stimulated thyroglobulin and thyroglobulin/thyroid-stimulating hormone ratio in differentiated thyroid cancer.
Lin Y; Li T; Liang J; Li X; Qiu L; Wang S; Chen Y; Kang Z; Li F
Clin Nucl Med; 2011 Dec; 36(12):1102-5. PubMed ID: 22064080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]